Share on StockTwits

BioSpecifics Technologies Corp. (NASDAQ:BSTC) Director Henry Morgan sold 20,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $25.84, for a total value of $516,800.00. Following the completion of the transaction, the director now directly owns 17,193 shares of the company’s stock, valued at approximately $444,267. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) traded up 1.08% on Wednesday, hitting $26.28. The stock had a trading volume of 24,398 shares. BioSpecifics Technologies Corp. has a 1-year low of $15.55 and a 1-year high of $27.86. The stock’s 50-day moving average is $25.05 and its 200-day moving average is $23.50. The company has a market cap of $167.9 million and a P/E ratio of 38.29.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) last announced its earnings results on Thursday, May 8th. The company reported $0.12 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.07 by $0.05. The company had revenue of $2.80 million for the quarter, compared to the consensus estimate of $2.46 million. On average, analysts predict that BioSpecifics Technologies Corp. will post $0.63 earnings per share for the current fiscal year.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.